Explore
Validate
Learn13086-1-AP
antibody from Proteintech Group
Targeting: FREM1
C9orf143, C9orf145, C9orf154, DKFZp686M16108, FLJ25461, TILRR
Western blot
ELISAAntibody data
- Antibody Data
- Antigen structure
- References [4]
- Comments [0]
- Validations
- Western blot [2]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 13086-1-AP - Provider product page
- Provider
- Proteintech Group
- Product name
- FREM1 antibody
- Antibody type
- Polyclonal
- Description
- FREM1 antibody (Cat. #13086-1-AP) is a rabbit polyclonal antibody that shows reactivity with human and has been validated for the following applications: IF, IHC, WB,ELISA.
- Reactivity
- Human
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 20ul, 150ul
Submitted references Central amygdala single-nucleus atlas reveals chromatin and gene transcription dynamics in human alcohol use disorder.
FREM1 serves as a novel therapeutic target in breast cancer through basement membrane-based prognostic modeling with integrated bioinformatics and experimental validation.
TILRR (FREM1 isoform 2) is a prognostic biomarker correlated with immune infiltration in breast cancer.
Elevated expression of FREM1 in breast cancer indicates favorable prognosis and high-level immune infiltration status.
Lee CY, Hwang A, McRiley D, Lee J, Thibodeau G, Duman C, Zhang X, Skarica M, Coudriet J, Xu S, Terwilliger R, Sliby AN, Wang J, Nguyen T, Liu Y, Li H, Dai Y, Duan Z, Lei Y, Lin Y, Glausier JR, Lewis DA, Gelernter J, Holtzheimer PE, Xu K, Zhou H, Zhao H, Thompson SL, Krystal JH, Che A, Taylor JR, Zhang J, Girgenti MJ
Nature communications 2026 Jan 19;17(1):1634
Nature communications 2026 Jan 19;17(1):1634
FREM1 serves as a novel therapeutic target in breast cancer through basement membrane-based prognostic modeling with integrated bioinformatics and experimental validation.
Li C, Gong P, Hu J, Luo C
Discover oncology 2025 Dec 1;17(1):15
Discover oncology 2025 Dec 1;17(1):15
TILRR (FREM1 isoform 2) is a prognostic biomarker correlated with immune infiltration in breast cancer.
Xu XY, Guo WJ, Pan SH, Zhang Y, Gao FL, Wang JT, Zhang S, Li HY, Wang R, Zhang X
Aging 2020 Oct 8;12(19):19335-19351
Aging 2020 Oct 8;12(19):19335-19351
Elevated expression of FREM1 in breast cancer indicates favorable prognosis and high-level immune infiltration status.
Li HN, Li XR, Lv ZT, Cai MM, Wang G, Yang ZF
Cancer medicine 2020 Dec;9(24):9554-9570
Cancer medicine 2020 Dec;9(24):9554-9570
No comments: Submit comment
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- HepG2 cells were subjected to SDS PAGE followed by western blot with 13086-1-AP( FREM1 Antibody) at dilution of 1:300
- Sample type
- cell line
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- The FREM1 antibody from Proteintech is a rabbit polyclonal antibody to a recombinant protein of human FREM1. This antibody recognizes human antigen. The FREM1 antibody has been validated for the following applications: ELISA, WB analysis.
